OncoMatch

OncoMatch/Clinical Trials/NCT06788912

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Is NCT06788912 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for lung neoplasm malignant.

Phase 2RecruitingMerck Sharp & Dohme LLCNCT06788912Data as of May 2026

Treatment: Pembrolizumab (neoadjuvant) · Cisplatin · Gemcitabine · Pemetrexed · Sacituzumab tirumotecan · H1 receptor antagonist · H2 receptor antagonist · Acetaminophen (or equivalent) · Dexamethasone (or equivalent) · Carboplatin · Pembrolizumab (adjuvant) · Paclitaxel · Steroid mouthwash (dexamethasone or equivalent)The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: EGFR wild-type

Disease stage

Required: Stage II, IIIA, IIIB (N2)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: radiation therapy

Exception: prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids

Received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Southern Cancer Center (SCC) ( Site 8004) · Daphne, Alabama
  • Sansum Clinic (Ridley Tree) ( Site 8012) · Santa Barbara, California
  • Rocky Mountain Cancer Centers (RMCC) ( Site 8011) · Lone Tree, Colorado
  • MedStar Franklin Square Medical Center ( Site 0033) · Baltimore, Maryland
  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8006) · Eugene, Oregon

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify